CUMYL-CH-MEGACLONE
CUMYL-CH-MEGACLONE (CUMYL-CHMGACLONE, SGT-270) is a gamma-carboline based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Hungary in December 2018.[1][2]
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C27H30N2O |
| Molar mass | 398.54 g·mol−1 |
| 3D model (JSmol) | |
| |
References
- Alam RM, Keating JJ (March 2020). "Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists". Drug Testing and Analysis. 12 (3): 297–315. doi:10.1002/dta.2752. PMID 31854124.
- Haschimi B, Giorgetti A, Mogler L, Nagy TZ, Kramer S, Halter S, et al. (June 2020). "The Novel Psychoactive Substance Cumyl-CH-MEGACLONE: Human Phase-I Metabolism, Basic Pharmacological Characterization, and Comparison to Other Synthetic Cannabinoid Receptor Agonists with a γ-Carboline-1-one Core". Journal of Analytical Toxicology. doi:10.1093/jat/bkaa065. PMID 32514544.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.